79.66
2.68 (3.48%)
| Penutupan Terdahulu | 76.98 |
| Buka | 76.92 |
| Jumlah Dagangan | 419,691 |
| Purata Dagangan (3B) | 600,279 |
| Modal Pasaran | 3,381,495,808 |
| Harga / Pendapatan (P/E Ke hadapan) | 135.14 |
| Harga / Jualan (P/S) | 8.84 |
| Harga / Buku (P/B) | 10.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -44.91% |
| Margin Operasi (TTM) | -33.55% |
| EPS Cair (TTM) | -2.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 183.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.13% |
| Nisbah Semasa (MRQ) | 5.57 |
| Aliran Tunai Operasi (OCF TTM) | -65.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.41 M |
| Pulangan Atas Aset (ROA TTM) | -16.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Tarsus Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.88 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.25% |
| % Dimiliki oleh Institusi | 110.77% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 100.00 (Mizuho, 25.53%) | Beli |
| Median | 88.00 (10.47%) | |
| Rendah | 87.00 (Guggenheim, 9.21%) | Beli |
| Purata | 91.67 (15.08%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 72.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 20 Nov 2025 | 100.00 (25.53%) | Beli | 76.98 |
| Guggenheim | 05 Nov 2025 | 87.00 (9.21%) | Beli | 68.20 |
| HC Wainwright & Co. | 20 Oct 2025 | 88.00 (10.47%) | Beli | 71.19 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Nov 2025 | Pengumuman | Tarsus to Participate in Upcoming Investor Conference |
| 05 Nov 2025 | Pengumuman | Tarsus to Participate in Upcoming Investor Conference |
| 04 Nov 2025 | Pengumuman | Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements |
| 28 Oct 2025 | Pengumuman | Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |